AR080747A1 - Proceso para preparar particulas de vehiculo para polvos secos para inhalacion - Google Patents

Proceso para preparar particulas de vehiculo para polvos secos para inhalacion

Info

Publication number
AR080747A1
AR080747A1 ARP110101070A ARP110101070A AR080747A1 AR 080747 A1 AR080747 A1 AR 080747A1 AR P110101070 A ARP110101070 A AR P110101070A AR P110101070 A ARP110101070 A AR P110101070A AR 080747 A1 AR080747 A1 AR 080747A1
Authority
AR
Argentina
Prior art keywords
particles
vehicle
pharmaceutical composition
inhalation
bromide
Prior art date
Application number
ARP110101070A
Other languages
English (en)
Inventor
Rossella Musa
Daniela Cocconi
Alain Chamayou
Laurence Galet
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42790618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080747(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR080747A1 publication Critical patent/AR080747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Proceso para preparar partículas de vehículo para usar en formulaciones en polvo seco para inhalacion, las partículas de vehículo que se pueden obtener mediante dicho proceso y las formulaciones farmacéuticas en polvo de las mismas. Reivindicacion 1: Un proceso para la preparacion de un vehículo para composiciones farmacéuticas en polvo para inhalacion, caracterizado porque el proceso comprende someter a partículas de lactosa, que tienen un diámetro de masa en el rango entre 30 y 1000 micrones a recubrimiento en seco con entre 0,1 y 1,3% de estearato de magnesio en peso del vehículo para proveer un recubrimiento superficial de las partículas de lactosa con dicho estearato de magnesio en una extension tal que las partículas recubiertas tienen más de 60% de recubrimiento superficial, en donde el paso de recubrimiento en seco se lleva a cabo en un granulador de alto esfuerzo de corte basado en el comportamiento de friccion a una velocidad de rotacion igual o mayor a 500 r.p.m., pero igual a o menor que 2500 r.p.m. Reivindicacion 8: Partículas de vehículo para una formulacion farmacéutica en polvo seco, caracterizadas porque dichas partículas de vehículo comprenden partículas de lactosa que tienen un diámetro de masa en el rango entre 30 y 1000 micrones recubiertas con entre 0,1 y 1,3% de estearato de magnesio en peso del vehículo a una extension tal que las partículas recubiertas tienen más de 60% de recubrimiento superficial, en donde dichas partículas de vehículo se pueden obtener mediante un proceso que comprende recubrimiento en seco en un granulador de alto esfuerzo de corte basado en el comportamiento de friccion a una velocidad de rotacion igual a o mayor que 500 r.p.m., pero igual a o menor que 2500 r.p.m. Reivindicacion 10: Una composicion farmacéutica en forma de polvo seco para inhalacion caracterizada porque comprende las partículas de vehículo de la reivindicacion 8 y uno o más ingredientes. Reivindicacion 11: La composicion farmacéutica de acuerdo a la reivindicacion 10, caracterizada porque el ingrediente activo comprende un agonista beta2 que se elige del grupo que consiste en salmeterol, formoterol, milveterol, vilanterol, olodaterol e indacaterol o una sal y/o solvato de los mismos. Reivindicacion 12: La composicion farmacéutica de acuerdo a la reivindicacion 10 u 11, caracterizada porque el ingrediente activo comprende un anticolinérgico que se elige del grupo que consiste en bromuro de tiotropio, bromuro de ipratropio, bromuro de oxitropio, cloruro de oxibutinina, bromuro de aclidinio, cloruro de trospio, bromuro de glicopirronio, GSK 573719 y GSK 1160274. Reivindicacion 13: La composicion farmacéutica de acuerdo a cualquiera de las reivindicaciones 10 a 12, caracterizada porque el ingrediente activo comprende un corticoesteroide que se elige del grupo que consiste en dipropionato de beclometasona, propionato de fluticasona, furoato de fluticasona, budesonide y furoato de mometasona. Reivindicacion 14: La composicion farmacéutica de acuerdo a cualquiera de las reivindicaciones 10 a 13, caracterizada porque el ingrediente activo comprende un inhibidor de fosfodiesterasa.
ARP110101070A 2010-04-01 2011-03-31 Proceso para preparar particulas de vehiculo para polvos secos para inhalacion AR080747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10158951 2010-04-01

Publications (1)

Publication Number Publication Date
AR080747A1 true AR080747A1 (es) 2012-05-02

Family

ID=42790618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101070A AR080747A1 (es) 2010-04-01 2011-03-31 Proceso para preparar particulas de vehiculo para polvos secos para inhalacion

Country Status (21)

Country Link
US (3) US8974831B2 (es)
EP (2) EP2552424B1 (es)
JP (2) JP5927175B2 (es)
KR (1) KR101730684B1 (es)
CN (2) CN104257610A (es)
AR (1) AR080747A1 (es)
AU (1) AU2011234751B2 (es)
BR (1) BR112012024059B1 (es)
CA (1) CA2794941C (es)
ES (1) ES2675575T3 (es)
HK (1) HK1204569A1 (es)
IL (1) IL222154A (es)
MX (1) MX336414B (es)
MY (1) MY162391A (es)
PL (1) PL2552424T3 (es)
RU (1) RU2585101C2 (es)
SG (1) SG184352A1 (es)
TR (1) TR201811349T4 (es)
TW (1) TWI491417B (es)
UA (1) UA110106C2 (es)
WO (1) WO2011120779A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
NZ627837A (en) * 2012-01-25 2016-04-29 Chiesi Farma Spa Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
JP6267685B2 (ja) * 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
EP2666465A1 (en) * 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
CN104955444A (zh) * 2012-12-27 2015-09-30 微剂量治疗公司 用于施用奥昔布宁的方法和组合物
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
SI3019153T1 (sl) 2013-07-11 2018-12-31 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
JP6397025B2 (ja) * 2013-11-22 2018-09-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 吸引可能薬剤
TN2017000077A1 (en) * 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제
CN105012278B (zh) * 2015-08-04 2017-12-29 广东省生物工程研究所（广州甘蔗糖业研究所） 一种干粉吸入粉雾剂载体蔗糖及其制备方法
CN107569474A (zh) * 2016-07-04 2018-01-12 正大天晴药业集团股份有限公司 一种可吸入干粉形式的药物组合物所用的载体的制备方法
TWI745396B (zh) * 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
EP3733167A4 (en) 2017-12-28 2021-09-08 Sumitomo Dainippon Pharma Co., Ltd. NEW COATING OF MICROPARTICLES (HOLLOW PARTICLES INCLUDING A MEDICINAL PRODUCT AND METHOD FOR MANUFACTURING THE SAME)
MX2020010928A (es) 2018-04-16 2020-11-06 Ioulia Tseti Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
CN109745564A (zh) * 2019-01-28 2019-05-14 上海方予健康医药科技有限公司 一种吸入干粉组合物的制备方法
BR112022004970A2 (pt) 2019-09-24 2022-08-23 Chiesi Farm Spa Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
KR20230066364A (ko) 2020-08-14 2023-05-15 노턴 (워터포드) 리미티드 플루티카손 프로피오네이트 및 알부테롤 술페이트의 흡입가능 제제
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS180644B2 (en) 1973-09-29 1978-01-31 Takeda Chemical Industries Ltd Process for preparing nonapeptides
NL7611963A (nl) 1975-10-29 1977-05-03 Parke Davis & Co Werkwijze voor het bereiden van nieuwe nonapep- tiden.
US4124577A (en) 1977-06-13 1978-11-07 Warner-Lambert Nonapeptides and methods for their production
US4317815A (en) 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
WO2000053157A1 (en) * 1999-03-05 2000-09-14 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
SI1386630T1 (sl) 2002-07-31 2006-10-31 Chiesi Farma Spa Inhalator za prasek
US20050220996A1 (en) * 2002-08-14 2005-10-06 Berger Larry L Process for coating a pharmaceutical particle
WO2004073827A1 (en) 2003-02-21 2004-09-02 The University Of Bath Process for the production of particles
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
GB0711680D0 (en) 2007-06-18 2007-07-25 Prosonix Ltd Process
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
CN101909652A (zh) 2007-11-07 2010-12-08 阿斯利康(瑞典)有限公司 含有抗坏血酸衍生物的干粉制剂
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
BRPI0915783A2 (pt) 2008-07-18 2018-05-22 Prosonix Ltd processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica ou agroquímica , e, inalador
WO2012041717A1 (en) 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation

Also Published As

Publication number Publication date
EP2762133A1 (en) 2014-08-06
PL2552424T3 (pl) 2018-10-31
KR20130029760A (ko) 2013-03-25
AU2011234751B2 (en) 2016-03-17
AU2011234751A1 (en) 2012-10-25
ES2675575T3 (es) 2018-07-11
EP2552424B1 (en) 2018-05-09
RU2012142295A (ru) 2014-05-10
US8974831B2 (en) 2015-03-10
BR112012024059A2 (pt) 2016-08-30
CN104257610A (zh) 2015-01-07
UA110106C2 (uk) 2015-11-25
MY162391A (en) 2017-06-15
KR101730684B1 (ko) 2017-04-26
CA2794941A1 (en) 2011-10-06
SG184352A1 (en) 2012-10-30
JP6162181B2 (ja) 2017-07-12
JP2015172097A (ja) 2015-10-01
TWI491417B (zh) 2015-07-11
US20150202159A1 (en) 2015-07-23
EP2552424A1 (en) 2013-02-06
IL222154A (en) 2016-02-29
MX2012010914A (es) 2012-10-10
TR201811349T4 (tr) 2018-09-21
TW201200163A (en) 2012-01-01
US20110262547A1 (en) 2011-10-27
JP5927175B2 (ja) 2016-06-01
JP2013523670A (ja) 2013-06-17
MX336414B (es) 2016-01-19
CN102858326A (zh) 2013-01-02
WO2011120779A1 (en) 2011-10-06
RU2585101C2 (ru) 2016-05-27
US9445999B2 (en) 2016-09-20
US20160354314A1 (en) 2016-12-08
BR112012024059B1 (pt) 2021-06-01
CA2794941C (en) 2018-05-15
HK1204569A1 (en) 2015-11-27

Similar Documents

Publication Publication Date Title
AR080747A1 (es) Proceso para preparar particulas de vehiculo para polvos secos para inhalacion
HRP20191686T1 (hr) Mikronizirane čestice aktivnih tvari za praškaste formulacije za inhalaciju u niskim dozama
SI2560611T1 (en) A process for preparing particles with reduced electrostatic charges
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
JP2019501876A5 (es)
US20150250713A1 (en) Pharmaceutical Composition
JP2013056928A5 (es)
MA39155A1 (fr) Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol
AR070834A1 (es) Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios
CA2827045A1 (en) Compositions of glycopyrrolate and a beta2-agonist
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
JP2015511241A5 (es)
ES2539612T3 (es) Formulaciones de partículas en polvo seco que contienen dos o más principios activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vías respiratorias
HRP20220929T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
HRP20200571T1 (hr) Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
HRP20211600T1 (hr) Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
ES2609821T3 (es) Inhaladores de polvo seco que comprenden un vehículo distinto de lactosa y un componente ternario
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
HRP20161340T1 (hr) Formulacije darunavira
IN2014DN11257A (es)
NZ630471A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
JP2017057223A5 (es)
AU2007346134A1 (en) Stable pharmaceutical drug aerosols
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.